Ask AI
Bill117th CongressFiled Jul 6, 2021Health
H.R. 4369

National Centers of Excellence in Advanced and Continuous Pharmaceutical Manufacturing Act of 2021

Bill journey · stage 2 of 5

Under committee review

Filed
Comm.
Floor
Both
Law

What it doesSummary passed house (Oct 19, 2021)

National Centers of Excellence in Advanced and Continuous Pharmaceutical Manufacturing Act of 2021

This bill directs the Food and Drug Administration (FDA) to designate qualified institutions of higher education (or consortia of such institutions) as National Centers of Excellence in Advanced and Continuous Pharmaceutical Manufacturing and to provide grants to the centers. Each designated center must conduct research on advanced and continuous pharmaceutical manufacturing technologies and must share information from such research with the FDA. (Currently, most drug production involves batch manufacturing, which typically takes longer than continuous manufacturing processes.)

What just happenedOct 20, 2021

Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Who’s behind it

Rep. Pallone, Frank, Jr. [D-NJ-6](D-NJ)Sponsor
1 cosponsor1 R
Read on Congress.gov
1cosponsors2committees21actions1related bills14subjects
  1. Oct 20, 2021IntroReferral

    Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

    Health, Education, Labor, and Pensions Committee
  2. Oct 19, 2021FloorH38800

    The title of the measure was amended. Agreed to without objection.

  3. Oct 19, 2021FloorH38310

    Motion to reconsider laid on the table Agreed to without objection.

  4. Oct 19, 2021FloorH37300

    On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 368 - 56 (Roll no. 318). (text: CR H5645-5647)

  5. Oct 19, 2021Floor8000

    Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 368 - 56 (Roll no. 318).(text: CR H5645-5647)

  6. Oct 19, 2021FloorH30000

    Considered as unfinished business. (consideration: CR H5662-5663)

  7. Oct 19, 2021FloorH37220

    At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.

  8. Oct 19, 2021FloorH8D000

    DEBATE - The House proceeded with forty minutes of debate on H.R. 4369.

  9. Oct 19, 2021FloorH30000

    Considered under suspension of the rules. (consideration: CR H5645-5647)

  10. Oct 19, 2021FloorH30300

    Mr. Pallone moved to suspend the rules and pass the bill, as amended.

  11. Oct 19, 2021CalendarsH12410

    Placed on the Union Calendar, Calendar No. 111.

  12. Oct 19, 2021CommitteeH12200

    Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 117-151.

    Energy and Commerce Committee
  13. Oct 19, 2021Committee5000

    Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 117-151.

    Energy and Commerce Committee
  14. Jul 21, 2021Committee

    Ordered to be Reported (Amended) by Voice Vote.

    Energy and Commerce Committee
  15. Jul 21, 2021Committee

    Committee Consideration and Mark-up Session Held.

    Energy and Commerce Committee
  16. Jul 15, 2021Committee

    Forwarded by Subcommittee to Full Committee (Amended) by Voice Vote .

    Health Subcommittee
  17. Jul 15, 2021Committee

    Subcommittee Consideration and Mark-up Session Held.

    Health Subcommittee
  18. Jul 7, 2021Committee

    Referred to the Subcommittee on Health.

    Health Subcommittee
  19. Jul 6, 2021IntroReferralH11100

    Referred to the House Committee on Energy and Commerce.

    Energy and Commerce Committee
  20. Jul 6, 2021IntroReferralIntro-H

    Introduced in House

  21. Jul 6, 2021IntroReferral1000

    Introduced in House

Passed HouseOct 19, 202153

National Centers of Excellence in Advanced and Continuous Pharmaceutical Manufacturing Act of 2021

This bill directs the Food and Drug Administration (FDA) to designate qualified institutions of higher education (or consortia of such institutions) as National Centers of Excellence in Advanced and Continuous Pharmaceutical Manufacturing and to provide grants to the centers. Each designated center must conduct research on advanced and continuous pharmaceutical manufacturing technologies and must share information from such research with the FDA. (Currently, most drug production involves batch manufacturing, which typically takes longer than continuous manufacturing processes.)

Introduced in HouseJul 6, 2021

National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2021

This bill directs the Food and Drug Administration (FDA) to designate qualified institutions of higher education as National Centers of Excellence in Continuous Pharmaceutical Manufacturing and to provide grants to the centers. Each designated center must conduct research on continuous manufacturing technologies and must share information from such research with the FDA. (Currently, most drug production involves batch manufacturing, which typically takes longer than continuous manufacturing processes.)

National Centers of Excellence in Advanced and Continuous Pharmaceutical Manufacturing Act… — Informed